What is Porton Advanced?
Founded in 2018 and headquartered in Suzhou, Jiangsu, Porton Advanced operates as a specialized therapy development platform provider. The company functions as a Contract Development and Manufacturing Organization (CDMO), offering comprehensive services that span the entire lifecycle of cell and gene therapy products. By integrating advanced manufacturing technologies with rigorous quality control standards, Porton Advanced positions itself as a vital partner for biotech innovators seeking to accelerate their clinical pipelines. Its market position is defined by a focus on high-growth therapeutic modalities, including viral vectors and cell-based therapies, which are increasingly central to modern precision medicine. The firm's ability to attract major institutional backing highlights its technical proficiency and its role in bridging the gap between laboratory-scale research and commercial-scale production.
How much funding has Porton Advanced raised?
Porton Advanced has raised a total of $80M across 1 funding round:
Series B
$80M
Series B (2022): $80M with participation from China Merchants Capital, Gortune Investment, SDICTK, Fosun Health Capital, and Merchant Health
Key Investors in Porton Advanced
China Merchants Capital
An alternative asset management firm backed by China Merchants Group, focusing on diversified investments across sectors including healthcare, advanced manufacturing, and infrastructure.
Gortune Investment
A professional investment institution specializing in private equity and venture capital, with a strong focus on high-growth industrial and technological sectors.
Fosun Health Capital
The healthcare-focused investment arm of Fosun Group, dedicated to supporting innovation in the pharmaceutical and medical technology industries.
What's next for Porton Advanced?
Looking ahead, the infusion of capital is expected to accelerate the expansion of Porton Advanced's manufacturing footprint and technical service offerings. The company is likely to prioritize the enhancement of its GMP-compliant facilities to meet the rising global demand for cell and gene therapy manufacturing. By leveraging this strategic financing, Porton Advanced aims to solidify its competitive advantage in the Asian market while simultaneously exploring international partnerships. Future growth will likely be driven by the continued optimization of its proprietary platform, enabling faster turnaround times for clients and fostering long-term sustainability in the rapidly evolving bioprocessing sector. The firm remains well-positioned to capitalize on the increasing outsourcing trends within the pharmaceutical industry, ensuring it remains a key enabler of next-generation medical breakthroughs.
See full Porton Advanced company page
